CPC A61K 31/36 (2013.01) [A61K 31/48 (2013.01); A61P 25/22 (2018.01)] | 4 Claims |
1. A method of treating a psychiatric disorder that affects mood including the step of:
administering a synergistic amount of 3,4-methylenedioxymethamphetamine (MDMA) in combination with a synergistic amount of LSD together in a single dosage form to a human individual, wherein MDMA is administered in a dose of 20-200 mg and LSD is administered in a dose of 0.05-0.3 mg, wherein said administration enhances a mood of the patient prior to administration of the psychedelic and improves good drug effects of blissful state and feeling open and reduces bad drug effects of anxiety as measured with psychometric assessments of Subjective Effects Questionnaire (Visual Analog Scales (VAS)) and 5-Dimensional Altered States of Consciousness ((5D-ASC), and wherein the MDMA enhances a positive over negative mood effect profile of the LSD in the individual; and
treating the psychiatric disorder that affects mood chosen from the group consisting of depression and anxiety.
|